MARKET OUTLOOK Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin condition that typically affects the face (cheeks), neck, arms, and legs but.
A pooled analysis of the TRuE-V1/TRuE-V2 phase 3 trials has shown that ruxolitinib (Opzelura) can help repigment the skin in multiple body areas, with lasting effects even in difficult areas.
FDA Approves First Topical JAK Inhibitor for Atopic Dermatitis medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.